Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose versus divided-dose aspirin for endothelial function in type 2 diabetes
IRCT20191101045301N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aspirin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Flow Mediated Dilation. Started Feb 2020; status: completed.
02
Drugs
aspirin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20191101045301N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191101045301N1.